Novartis buys Kate Therapeutics in $1.1B deal, eyes more bolt-on M&A

Novartis is buying gene therapy and neuroscience biotech Kate Therapeutics in a deal worth $1.1 billion in upfront and milestone payments, the Swiss pharma confirmed to Endpoints News on Thursday. And Novartis is not done ...